KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Current Deferred Revenue (2016 - 2025)

Moderna (MRNA) has disclosed Current Deferred Revenue for 9 consecutive years, with $163.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Current Deferred Revenue changed N/A to $163.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $163.0 million, a N/A change, with the full-year FY2024 number at $153.0 million, down 76.5% from a year prior.
  • Current Deferred Revenue was $163.0 million for Q3 2025 at Moderna, down from $218.0 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $8.0 billion in Q3 2021 to a low of $20.0 million in Q2 2024.
  • A 5-year average of $2.9 billion and a median of $1.6 billion in 2023 define the central range for Current Deferred Revenue.
  • Peak YoY movement for Current Deferred Revenue: soared 12698.68% in 2021, then crashed 98.85% in 2024.
  • Moderna's Current Deferred Revenue stood at $6.9 billion in 2021, then plummeted by 70.33% to $2.0 billion in 2022, then plummeted by 68.06% to $651.0 million in 2023, then plummeted by 76.5% to $153.0 million in 2024, then rose by 6.54% to $163.0 million in 2025.
  • Per Business Quant, the three most recent readings for MRNA's Current Deferred Revenue are $163.0 million (Q3 2025), $218.0 million (Q2 2025), and $183.0 million (Q1 2025).